Joseph Bishop

Directeur/Membre du Conseil chez ARBUTUS BIOPHARMA CORPORATION

51 ans

Finance

Health Technology

Profil

Joseph Bishop is an Independent Director at Arbutus Biopharma Corp.
since 2025.
Mr. Bishop is Senior Vice President-Finance at Roivant Social Ventures, Inc. since 2024.
Formerly, Mr. Bishop was a Portfolio Manager at Intrepid Capital Management, Inc. (Connecticut) from 2001 to 2010.
Mr. Bishop was a Portfolio Manager at Citadel Enterprise Americas LLC from 2010 to 2012.
Mr. Bishop was Portfolio Manager & Head-Equities at Pine River Capital Management LLC from 2013 to 2017.
Mr. Bishop completed undergraduate education at the Massachusetts Institute of Technology.

Postes actifs de Joseph Bishop

Sociétés	Poste	Début
ARBUTUS BIOPHARMA CORPORATION	Directeur/Membre du Conseil	24/02/2025
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016.	Directeur Financier/CFO	-

Tous les postes actifs de Joseph Bishop

Anciens postes connus de Joseph Bishop

Sociétés	Poste	Fin
Pine River Capital Management LLC Pine River Capital Management LLC Investment ManagersFinance Provides asset management and investment services	Corporate Officer/Principal	01/01/2017
Citadel Enterprise Americas LLC Citadel Enterprise Americas LLC Investment ManagersFinance Citadel Enterprise invests in public equity, fixed income and alternative investment markets across the globe. The firm seeks to identify the highest and best uses of capital to generate superior long-term returns for their clients.	Corporate Officer/Principal	01/01/2012
Intrepid Capital Management, Inc. (Connecticut) Intrepid Capital Management, Inc. (Connecticut) Investment ManagersFinance Intrepid Capital Management is a value manager that employs a conservative, contrarian investment strategy. The firm invests long/short in global equities without regard to market-cap. They invest in derivatives including options, warrants, convertibles and index options and employ leverage to hedge their portfolios. Intrepid uses fundamental research to identify stocks with reasonable valuations that are misunderstood by the market, focusing on cash flow and price-to-sales ratios. The firm may occasionally invest in private equity opportunities.	Corporate Officer/Principal	01/01/2010

Voir l'expérience en détail de Joseph Bishop

Formation de Joseph Bishop

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Joseph Bishop

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	6
Intrepid Capital Management, Inc. (Connecticut) Intrepid Capital Management, Inc. (Connecticut) Investment ManagersFinance Intrepid Capital Management is a value manager that employs a conservative, contrarian investment strategy. The firm invests long/short in global equities without regard to market-cap. They invest in derivatives including options, warrants, convertibles and index options and employ leverage to hedge their portfolios. Intrepid uses fundamental research to identify stocks with reasonable valuations that are misunderstood by the market, focusing on cash flow and price-to-sales ratios. The firm may occasionally invest in private equity opportunities.	Finance
Arbutus Biopharma Corp. Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases	Health Technology
Citadel Enterprise Americas LLC Citadel Enterprise Americas LLC Investment ManagersFinance Citadel Enterprise invests in public equity, fixed income and alternative investment markets across the globe. The firm seeks to identify the highest and best uses of capital to generate superior long-term returns for their clients.	Finance
Pine River Capital Management LLC Pine River Capital Management LLC Investment ManagersFinance Provides asset management and investment services	Finance
Massachusetts Institute of Technology Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University	Finance
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016.